HBeAg阴性慢性乙型肝炎停用口服抗病毒药后复发定义的意义
本研究纳入130例无肝硬化、接受核苷(酸)类似物治疗且病毒学缓解≥24个月的HBeAg阴性慢性乙型肝炎患者,评估不同复发定义对停药后复发率及再治疗概率的影响。中位治疗60个月,停药随访15个月,不同定义下累积复发率差异大(3个月2%-49%,24个月16%-90%),而再治疗率6个月15%、12个月22%、24个月40%。结论认为复发定义显著影响复发率及再治疗概率,严格标准下部分患者可能无需再治疗。
要点
- 不同复发定义使停药后累积复发率差异很大(3个月2%-49%,24个月16%-90%)。
- 严格再治疗标准下,停药后6、12、24个月累积再治疗率分别为15%、22%、40%。
- 基于至少两种定义或再治疗的复发概率均无患者特征独立相关。
核心结论
- 在停用核苷(酸)类似物的HBeAg阴性慢性乙型肝炎患者中,复发定义对停药后复发率及再治疗概率影响很大。
- 无论采用何种定义,停药后复发均难以通过患者特征预测。
- 若采用严格标准,相当比例患者可能无需再治疗。
研究设计与样本
- 本研究纳入130例无肝硬化、未接受过核苷(酸)类似物治疗的HBeAg阴性慢性乙型肝炎患者。
- 所有患者治疗期间病毒学缓解≥24个月,停药后密切随访≥12个月或直至再治疗,再治疗依据严格的预定标准。
- 中位治疗时长60个月,治疗期间中位病毒学缓解时长43个月,停药后中位随访15个月。
主要发现
- 停药后中位随访15个月期间,无患者发生肝衰竭或死亡。
- 累积复发率在3、6、12、24个月分别为2%-49%、4%-73%、11%-82%、16%-90%(不同定义下范围)。
- 累积再治疗率在停药后6、12、24个月分别为15%、22%、40%。
- 基于至少两种定义或再治疗的复发概率均无患者特征独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Relapses are observed in most hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who discontinue treatment with nucleos(t)ide analogues (NAs); however, the rates of relapse vary widely among studies, and whether all patients with relapse need retreatment is unclear. The aim of this study was to assess the impact of different definitions on the rates of posttreatment relapse and therefore on the probability of retreatment in patients who have discontinued effective long-term NA therapy. In total, 130 HBeAg-negative chronic hepatitis B patients without cirrhosis and before NA treatment were included. All had on-therapy virological remission for ≥24 months and close follow-up for ≥12 months after stopping NA treatment or until retreatment, which started on stringent predefined criteria. Relapses rates based on several predetermined definitions of virological and perhaps biochemical criteria were assessed. The median duration of therapy was 60 months and the median duration of on-therapy virological remission was 43 months. During a median off-NAs follow-up of 15 months, no patient experienced liver decompensation or died. Cumulative relapse rates were 2%-49%, 4%-73%, 11%-82%, and 16%-90% at 3, 6, 12, and 24 months, respectively, whereas cumulative retreatment rates were 15%, 22%, and 40% at 6, 12, and 24 months, respectively, after discontinuation of NA therapy. No patient characteristic was independently associated with the probability of relapse based on at least two definitions or of retreatment. CONCLUSION: In HBeAg-negative chronic hepatitis B patients who discontinue NA therapy, the definition of relapse has a great impact on off-NAs relapse rates and potentially on the probability of retreatment. Regardless of definition, off-NAs relapses cannot be easily predicted by patient characteristics. A substantial proportion of such patients may not require retreatment if stringent criteria are adopted. (Hepatology 2017).
引用
- Papatheodoridis GV, Manolakopoulos S, Su TH, et al. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. Hepatology. 2018. PMID: 28859219. doi:10.1002/hep.29497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。